Agilent Technologies announced it will showcase its latest advancements in precision oncology and digital pathology at the USCAP 2026 Annual Meeting in San Antonio.

The company will highlight expanded biomarker testing capabilities, including a new PD-L1 indication for ovarian-related cancers, reinforcing its focus on precision oncology. Agilent will also present end-to-end digital pathology workflows that integrate staining, imaging, and data management to improve laboratory efficiency, reproducibility, and scalability.

Additionally, Agilent emphasized collaborations with ecosystem partners such as Hamamatsu, Proscia, PathAI, and Visiopharm to support interoperable and flexible digital pathology solutions, positioning the company to advance data-driven and fully integrated pathology environments.